Eupraxia Pharmaceuticals (TSX:EPRX) Days Payable: 0.00 (As of Mar. 2026)


TSX:EPRX Eupraxia Pharmaceuticals Inc TSX:EPRX
36 GF Score
Price C$9.31
! 1 Warning Sign
View Full Analysis

What is Eupraxia Pharmaceuticals Days Payable?

Eupraxia Pharmaceuticals TSX:EPRX -0.43% 36 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates TSX:EPRX with a GF Score™ of 36/100. The stock has 1 warning sign investors should review. Among 703 Biotechnology companies, Eupraxia Pharmaceuticals ranks worse than 142247.37% on this metric.

Eupraxia Pharmaceuticals's average Accounts Payable for the three months ended in Mar. 2026 was C$0.00 Mil. Eupraxia Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2026 was C$0.00 Mil.

The historical rank and industry rank for Eupraxia Pharmaceuticals's Days Payable or its related term are showing as below:

TSX:EPRX's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.76
* Ranked among companies with meaningful Days Payable only.

Eupraxia Pharmaceuticals's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Eupraxia Pharmaceuticals Days Payable Historical Data

* Premium members only.

The historical data trend for Eupraxia Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eupraxia Pharmaceuticals Days Payable Chart

Eupraxia Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Days Payable
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Eupraxia Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSX:EPRX vs VRTX, REGN, ALNY: Days Payable Comparison

For the Biotechnology subindustry, Eupraxia Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eupraxia Pharmaceuticals Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Eupraxia Pharmaceuticals's Days Payable falls into.


TSX:EPRX
36GF Score
Eupraxia Pharmaceuticals Inc TSX:EPRX
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eupraxia Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Eupraxia Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

Days Payable (A: Dec. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2024 ) + Accounts Payable (A: Dec. 2025 )) / count ) / Cost of Goods Sold (A: Dec. 2025 )*Days in Period
=( (0 + 0) / 1 ) / 0*365
=0 / 0*365
=N/A

Eupraxia Pharmaceuticals's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

Days Payable (Q: Mar. 2026 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2025 ) + Accounts Payable (Q: Mar. 2026 )) / count ) / Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=( (0 + 0) / 1 ) / 0*365 / 4
=0 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Eupraxia Pharmaceuticals (TSX:EPRX) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Eupraxia Pharmaceuticals and its competitors. According to the industry distribution chart, Eupraxia Pharmaceuticals ranks #999999 out of 703 companies in the Biotechnology industry.
Is Eupraxia Pharmaceuticals' Days Payable too high?
Eupraxia Pharmaceuticals' current Days Payable is 0.00. Based on the distribution chart, Eupraxia Pharmaceuticals ranks #999999 out of 703 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Eupraxia Pharmaceuticals has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Eupraxia Pharmaceuticals' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Eupraxia Pharmaceuticals ranks #999999 out of 703 companies for Days Payable. This places Eupraxia Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 113.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Eupraxia Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eupraxia Pharmaceuticals's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eupraxia Pharmaceuticals stock overvalued right now?
Eupraxia Pharmaceuticals (TSX:EPRX) has a current Days Payable of 0.00. The current Days Payable is 0.00. Eupraxia Pharmaceuticals' overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Eupraxia Pharmaceuticals (TSX:EPRX), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eupraxia Pharmaceuticals Business Description

Other Exchanges EPRX:USAX43:Germany
Address 201 2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
36GF Score

Get the complete analysis for TSX:EPRX

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$9.31
Price